伊帕利塞普(OMP54F28)联合紫杉醇和卡铂治疗复发性铂敏感卵巢癌的1b期剂量递增研究
本研究为1b期剂量递增试验,评估伊帕利塞普(IPA)联合紫杉醇/卡铂(C/P)治疗复发性铂敏感卵巢癌的最大耐受剂量和推荐2期剂量。37例患者接受治疗,未达到最大耐受剂量,基于骨安全性的最大给药剂量为6 mg/kg,总体缓解率75.7%,中位无进展生存期10.3个月,总生存期33个月。结论认为IPA联合序贯C/P耐受良好,但该Wnt抑制剂在有效剂量下的骨毒性限制了其在卵巢上皮癌中的进一步开发。
要点
- IPA联合紫杉醇/卡铂未达到最大耐受剂量,基于骨安全性的最大给药剂量为6 mg/kg。
- 总体缓解率75.7%,中位无进展生存期10.3个月(95%CI 8.5-14.2),总生存期33个月(95%CI 23.4-未达到)。
- 该Wnt抑制剂在有效剂量下的骨毒性限制了其在卵巢上皮癌中的进一步开发。
核心结论
- IPA联合序贯紫杉醇/卡铂耐受良好,总体缓解率、无进展生存期和总生存期与历史数据相当,但该特定Wnt抑制剂在有效剂量下的骨毒性限制了其在卵巢上皮癌中的进一步开发。
研究设计与样本
- 1b期剂量递增试验,采用标准3+3设计,起始方案为第1天静脉给予IPA,第1至6周期联合卡铂(AUC=5 mg/ml·min)和紫杉醇(175 mg/m2),每3周一次。
- 为增强骨安全性,试验修订为6例患者队列,每3周第1天给予IPA、第3天给予卡铂/紫杉醇(IPA→C/P)。
- 共37例患者接受治疗,其中30例在方案修订后接受每3周第1天IPA、第3天C/P治疗(2和4 mg/kg)。
主要发现
- 发生率≥15%的IPA相关治疗中出现的不良事件包括:疲乏(40%)、恶心(35%)、腹泻和食欲下降(各22%)、味觉障碍(19%)、呕吐(16.2%)。
- 22%的患者报告至少1项IPA相关≥3级治疗中出现的不良事件,最常见为中性粒细胞减少(16%)。
- 未观察到剂量限制性毒性,未达到最大耐受剂量,基于骨安全性的最大给药剂量为6 mg/kg。
- 总体缓解率为75.7%,中位无进展生存期为10.3个月(95%CI 8.5-14.2),中位总生存期为33个月(95%CI 23.4-未达到)。
局限性
- 该特定Wnt抑制剂在有效剂量下的骨毒性限制了其在卵巢上皮癌中的进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P). METHODS: Dose escalation started with a standard 3 + 3 design for IPA/C/P with q3w intravenous IPA on Day 1, in cycles 1 to 6 with C (AUC = 5 mg/ml·min) and P (175 mg/m2). For enhanced bone safety the trial was revised to 6-patient cohorts with a q3w regimen of IPA on Day 1 and C/P on Day 3 (IPA → C/P). RESULTS: 37 patients have been treated; 30 of whom were treated following protocol revision to q3w IPA(D1) → C/P(D3) (2 & 4 mg/kg). IPA-related TEAEs that occurred in ≥15% included: fatigue (40%); nausea (35%); diarrhea and decreased appetite (22%) each; dysgeusia (19%); and vomiting (16.2%). 22% reported ≥1 IPA related TEAE Grade ≥3 the most common of which was neutropenia at 16%. There were no DLTs; the MTD was not reached. The maximum administered dose based on bone safety was 6 mg/kg. The overall response rate (ORR) was 75.7%. Median PFS was 10.3 months (95% CI 8.5-14.2) and OS 33 months (95% CI 23.4-NR). CONCLUSIONS: IPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC.
引用
- Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019. PMID: 31174889. doi:10.1016/j.ygyno.2019.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。